Inclusion Criteria:

          -  Diagnosed with a locally advanced or metastatic malignancy that has progressed despite
             standard therapy, or for which no effective standard therapy exists

          -  Age ≥ 12 months and < 18 years

          -  The tumor must carry a genetic alteration of ALK

          -  Patients must have evaluable or measurable disease.

          -  Karnofsky performance status score ≥ 60% for patients > 12 years of age; Lansky score
             ≥ 50% for patients ≤ 12 years of age.

        Exclusion criteria:

          -  Symptomatic central nervous system (CNS) metastases who are neurologically unstable or
             require increasing doses of steroids or local CNS-directed therapy (such as
             radiotherapy, surgery or intrathecal chemotherapy) to control their CNS disease

          -  Inadequate end organ function as defined by specified laboratory values

          -  Body surface area (BSA) < 0.35 m2

          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly
             alter the absorption of LDK378 (e.g., ulcerative diseases, uncontrolled nausea,
             vomiting, diarrhea, or malabsorption syndrome)

          -  Use of medications that are known to be strong inhibitors or inducers of CYP3A4/5 that
             cannot be discontinued at least 1 week prior to start of treatment with LDK378 and for
             the duration of the study

          -  Use of medications that are mainly metabolized by CYP3A4/5 or CYP2C9 that cannot be
             discontinued at least 1 week prior to start of treatment with LDK378 and for the
             duration of the study

          -  History of interstitial lung disease or interstitial pneumonitis, including clinically
             significant radiation pneumonitis

          -  History of pancreatitis or history of increased amylase or lipase that was due to
             pancreatic disease.

          -  Medications with a known risk of prolongation of QT interval